



Welireg in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · HIF-2A FOR VHL / RCC

The clinical situation

Welireg (belzutifan) is an oral selective HIF-2 α inhibitor for VHL disease-associated tumours (RCC, CNS haemangioblastoma, pancreatic NET not requiring immediate surgery) and advanced renal cell carcinoma after specified prior therapy. Manufactured by Merck. Dosing is 120 mg orally once daily. Clinically significant adverse events include anaemia and hypoxia requiring haemoglobin and oximetry monitoring; embryo-fetal toxicity requires contraception counselling.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your oncologist or VHL-specialty team confirms germline VHL variant (for VHL indication) or RCC indication and writes the rationale letter.
- 2 Baseline assessment.** Haemoglobin, oximetry, renal and hepatic function, and pregnancy-status verification where applicable.
- 3 SFDA named-patient application.** Rationale, patient reference, genetic/imaging documentation, and dosing plan filed.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner.
- 5 Initiation & ongoing monitoring.** Your oncology team initiates; haemoglobin and oximetry monitoring per FDA labelling.

Indicative economics

Reference US cash-pay range: USD 26,000–32,000 per 30-day supply at 120 mg daily (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and SFDA review, keyed to the VHL or advanced RCC rationale. **Logistics.** Temperature-controlled shipment with importer-of-record handling. **Concierge case lead.** Named point of contact for family and oncology team. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Welireg × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/welireg-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team